One in four providers said that health technology vendors haven’t kept their promises in the past year. KLAS Research debunked four common misconceptions vendors may have about why so many providers feel this way such as the false notion that employees who weren't part of the purchasing decision feel the most disappointed by vendors or the misbelief that it's better to not make promises in the first place.
When we bring physicians from underserved communities into research through a reimagined model, we can impact better health outcomes rooted in quality data that allows us to thrive from more diversity and better representation while providing patients with greater access to new care options.
Amino Health's $80 million in financing was led by Transformation Capital and Oxford Finance. With the funding, the company hopes to reach and engage more members and grow its partnerships with employers and third party administrators.
Nido Biosciences’ lead drug hits a previously undrugged pocket as a way to potentially treat the rare neuromuscular disorder spinal and bulbar muscular atrophy. The startup’s tech platform screens neurons to find targets for new neurological disorder drugs.
By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic . The royalty deal extends uniQure’s cash runway into 2026.